GULLO2 Antibody
Description
Definition and Target
GULLO2 Antibody is a rabbit-derived polyclonal antibody targeting L-gulonolactone oxidase 2 (GULLO2), an enzyme encoded by the GULLO2 gene (At2g46750) in Arabidopsis thaliana. This enzyme is part of the L-gulonolactone oxidase family (EC 1.1.3.8), which catalyzes the final step in ascorbic acid (vitamin C) biosynthesis in plants .
Antibody Development and Specificity
Cross-Reactivity and Validation
The antibody has been validated for use in Western Blot (WB) and Enzyme-Linked Immunosorbent Assay (ELISA). No cross-reactivity with non-target species or isoforms (e.g., GULLO1, GULLO3–7) has been reported .
Applications in Research
GULLO2 Antibody is primarily used to:
-
Detect and quantify GULLO2 protein expression in Arabidopsis thaliana tissues.
-
Investigate the role of GULLO2 in ascorbic acid biosynthesis and stress responses.
-
Study enzyme localization and regulation under varying physiological conditions.
Research Context
While direct studies using GULLO2 Antibody are not detailed in the provided sources, its utility aligns with broader research on Arabidopsis thaliana:
-
Iron Deficiency Responses: GULLO2 homologs (e.g., GULLO6) are implicated in iron metabolism, as seen in barley cultivars where L-gulonolactone oxidase activity correlates with stress tolerance .
-
Enzyme Function: GULLO2’s role in vitamin C synthesis may link it to oxidative stress mitigation, though further studies are needed .
Limitations and Future Directions
-
Species Restriction: Reactivity is limited to Arabidopsis thaliana, restricting cross-species studies.
-
Functional Data Gap: Mechanistic insights into GULLO2’s biochemical pathways remain sparse.
-
Commercial Development: Enhanced validation (e.g., knockout controls) would strengthen reliability.
Product Specs
Target Background
Q&A
FAQs for Researchers on GluD2 Antibody (Glutamate Receptor Delta 2)
How can researchers validate the specificity of GluD2 antibodies in immunohistochemistry (IHC)?
To ensure specificity, use a combination of techniques:
-
Positive controls: Include commercial GluD2 antibodies (e.g., Sino Biologicals, Frontier Institute Japan) that show expected reactivity with molecular and Purkinje cell layers in cerebellar tissue .
-
Preabsorption tests: Incubate antibodies with HEK293T cells expressing GluD2 to confirm antigen-specific binding .
-
Cross-validation with cell-based assays (CBA): Compare IHC results with live CBAs using plasmids encoding GluD2. Discordant results (e.g., nonspecific CBA reactivity) indicate methodological artifacts .
What are the primary applications of GluD2 antibodies in neurobiological research?
GluD2 antibodies are used to:
-
Map synaptic distribution in cerebellar circuits (e.g., molecular layer and Purkinje cells) .
-
Study calcium permeability regulation in AMPA receptors, particularly in interneurons co-expressing calcium-binding proteins .
-
Investigate autoimmune mechanisms in paraneoplastic disorders like opsoclonus-myoclonus syndrome (OMS) .
How should researchers design assays to minimize false positives in GluD2 antibody detection?
-
Avoid 3-step CBA methods: These increase nonspecific reactivity (e.g., 27% equivocal results vs. 0% with 2-step CBA) .
-
Use age-matched tissue: GluD2 expression varies developmentally; prenatal cerebellar tissue may yield misleading immunoreactivity .
-
Include disease controls: Test sera from patients with neuroblastoma without OMS to rule out tumor-associated cross-reactivity .
How can conflicting data on GluD2 antibodies in OMS be resolved?
A 2021 study (N=203 OMS patients) found no GluD2 antibodies using rigorous validation , contradicting earlier reports . To resolve discrepancies:
-
Replicate methods: Previous studies used prenatal cerebellar tissue, which may precipitate non-GluD2 antigens .
-
Standardize antigen sources: Use adult rat cerebellum, where GluD2 is enriched in molecular layers .
-
Blinded validation: Retest archived sera with both IHC and CBA in parallel .
Table 1: Key findings from GluD2 antibody studies in OMS
| Assay Type | OMS Patients (n=203) | Controls (n=172) | Notes |
|---|---|---|---|
| 2-step CBA | 0% positive | 0% positive | Gold standard for specificity |
| 3-step CBA | 0% positive | 27% equivocal | High nonspecific background |
| Cerebellar IHC | 0% positive | 0% positive | Matches GluD2 expression sites |
What computational approaches improve antibody-antigen binding prediction for GluD2?
-
Active learning frameworks: Prioritize high-value experiments by iteratively training models on library-on-library screening data (e.g., reduces required antigen variants by 35%) .
-
Epitope mapping: Use molecular dynamics simulations to compare germline vs. affinity-matured antibodies, as demonstrated for GD2-targeting therapeutics .
How does germline antibody evolution inform GluD2-targeted therapeutic design?
-
Germline specificity: Anti-GD2 antibodies (e.g., ch14.18) evolved from highly selective germline precursors without polyspecificity . Apply similar principles to engineer GluD2 antibodies with minimal off-target binding.
-
Affinity maturation: Use phage display libraries with random H/L chain combinations to diversify epitope recognition .
Methodological Recommendations
-
For neurodegenerative studies: Combine GluD2 IHC with calcium-binding protein co-localization assays (e.g., parvalbumin, calretinin) .
-
In autoimmune research: Pair GluD2 antibody screening with tumor profiling (34% of adult OMS cases are paraneoplastic) .
-
For machine learning: Integrate Absolut! simulation frameworks to predict out-of-distribution antibody-antigen interactions .
